Compare Heron Therapeutics Inc (HRTX) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs iShares MSCI China ETF — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while iShares MSCI China ETF trades at $52.55 (market cap $5.94B). The key difference: iShares MSCI China ETF is far larger — about 87.3× Heron Therapeutics Inc's market cap, and Heron Therapeutics Inc is more actively traded (1,891,941 versus 1,575,471). Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and iShares MSCI China ETF for 63 Days on average.
| HRTX | MCHI | |
|---|---|---|
Market Cap | $68.01M | $5.94B |
Volume | 1,891,941 | 1,575,471 |
Sector | Health | Broad Market / Factor |
52-Week High | $1.49 | $65.59 |
52-Week Low | $0.27 | $50.48 |
Typical Hold Time | 35 Days | 63 Days |
Enterprise Value | $174.75M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3582, down 8.15% today, with a bullish technical signal from moving averages but mixed earnings. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates, continuing a trend of net losses. Analyst sentiment remains strongly positive with 89% buy ratings, though Zacks issued a Strong Sell rating in July 2026.
The outlook hinges on revenue stabilization and path to profitability. Investment opportunity lies in analyst optimism and product sales growth, but risks include persistent losses, high valuation multiples, and competitive pressures in the biotechnology sector.
MCHI trades at $51.36, down 0.54% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges including industrial overcapacity and weak domestic consumption. Recent news highlights trade tensions ahead of U.S.-China talks, though corporate profits surged 26% in Q2. Technical indicators show oversold conditions with RSI at 25.44 suggesting potential for near-term bounce.
The outlook remains cautious given China's macroeconomic pressures and trade uncertainties. Investment opportunity exists in MCHI's significant discount to historical valuations versus U.S. indices. Key risks include potential export controls, protectionism threats, and China's reliance on infrastructure spending rather than broad stimulus to support growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
